Biostage Stock Shares Owned By Insiders
| BSTGDelisted Stock | USD 4.20 0.09 2.10% |
Biostage fundamentals help investors to digest information that contributes to Biostage's financial success or failures. It also enables traders to predict the movement of Biostage OTC Stock. The fundamental analysis module provides a way to measure Biostage's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biostage otc stock.
Biostage |
Biostage OTC Stock Shares Owned By Insiders Analysis
Biostage's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Biostage Shares Owned By Insiders | 50.95 % |
Most of Biostage's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biostage is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 50% of Biostage are shares owned by insiders. This is 235.64% higher than that of the Biotechnology sector and 259.31% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Biostage Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostage's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Biostage could also be used in its relative valuation, which is a method of valuing Biostage by comparing valuation metrics of similar companies.Biostage is currently under evaluation in shares owned by insiders category among its peers.
Biostage Fundamentals
| Return On Equity | -4.92 | |||
| Return On Asset | -2.11 | |||
| Current Valuation | 78.64 M | |||
| Shares Outstanding | 11.64 M | |||
| Shares Owned By Insiders | 50.95 % | |||
| Number Of Shares Shorted | 121.66 K | |||
| Price To Earning | (0.16) X | |||
| Price To Book | 28.47 X | |||
| EBITDA | (8.36 M) | |||
| Net Income | (7.98 M) | |||
| Cash And Equivalents | 4.64 M | |||
| Cash Per Share | 0.40 X | |||
| Total Debt | 115 K | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 2.26 X | |||
| Book Value Per Share | (0.16) X | |||
| Cash Flow From Operations | (2.63 M) | |||
| Short Ratio | 3.35 X | |||
| Earnings Per Share | (0.89) X | |||
| Target Price | 3.0 | |||
| Beta | -0.91 | |||
| Market Capitalization | 73.82 M | |||
| Total Asset | 1.87 M | |||
| Retained Earnings | (65.78 M) | |||
| Working Capital | 7.23 M | |||
| Current Asset | 7.88 M | |||
| Current Liabilities | 654 K | |||
| Net Asset | 1.87 M |
About Biostage Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostage's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostage using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostage based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Biostage OTC Stock
If you are still planning to invest in Biostage check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostage's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |